NCT07353645 2026-04-15
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2 Recruiting
Clinical Trials
78 trialsNCT07403136 2026-04-15
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
Fudan University
Phase 2 Suspended
NCT03983057 2026-02-11
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
Zhejiang University
Phase 2 Completed
NCT07381309 2026-02-02
VVSHIP
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07365592 2026-01-26
Neo-CD
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting
NCT06468280 2026-01-21
ROSETTE
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT04146298 2025-12-24
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Changhai Hospital
Phase 1/2 Recruiting
NCT07277842 2025-12-11
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06493240 2025-11-25
NLCCRIT-LARC
Peking University People's Hospital
Phase 2 Completed
NCT07007182 2025-09-05
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT05576480 2025-08-28
SPARC
Ruijin Hospital
Phase 2 Recruiting
NCT04191421 2025-08-22
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
Emory University
Phase 1/2 Completed
NCT06507371 2025-06-26
mRCAT-III
Sir Run Run Shaw Hospital
Phase 3 Recruiting
NCT06728657 2025-06-18
TORCH-G
Fudan University
Phase 2 Suspended
NCT04821765 2025-05-30
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT06280495 2025-05-30
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
Phase 2/3 Recruiting
NCT06908031 2025-05-14
CRIT
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting
NCT06794086 2025-05-13
SPARKLE-L
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT04581343 2025-05-04
PanCAN-SR1
Pancreatic Cancer Action Network
Phase 1 Completed
NCT06928584 2025-04-15
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Fudan University
Phase 2 Recruiting
NCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT04802876 2025-03-21
ACROPOLI
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT04866836 2025-03-21
A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Terminated
NCT06840665 2025-02-21
MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
Fudan University
Phase 2 Recruiting
NCT06792162 2025-01-24
PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Peking University Third Hospital
Phase 2 Recruiting
NCT04518280 2025-01-17
TORCH
Fudan University
Phase 2 Completed
NCT05555888 2025-01-15
TORCH-E
Fudan University
Phase 2 Recruiting
NCT06417892 2025-01-14
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recruiting
NCT05972655 2025-01-09
mRCAT
Sir Run Run Shaw Hospital
Phase 2 Recruiting
NCT06665087 2024-10-30
CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC
Fudan University
Phase 2 Not yet recruiting
NCT05628038 2024-10-01
TORCH-R
Fudan University
Phase 2 Recruiting
NCT03716596 2024-09-20
CISPD-2
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Terminated
NCT06349044 2024-08-27
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
Zhejiang Cancer Hospital
Phase NA Recruiting
NCT05717738 2024-06-13
CCGLC-008
Tongji Hospital
Recruiting
NCT06455124 2024-06-13
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
Fudan University
Phase 2 Recruiting
NCT03291054 2024-06-11
Epacadostat and Pembrolizumab in Patients With GIST
Columbia University
Phase 2 Terminated
NCT06396637 2024-05-02
PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC
Sun Yat-sen University
Phase 2 Recruiting
NCT04301557 2024-04-23
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06364787 2024-04-15
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma
Beijing 302 Hospital
Phase 1 Not yet recruiting
NCT06364800 2024-04-15
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody
Beijing 302 Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT06298123 2024-03-07
Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling
Tongji Hospital
Completed
NCT06121700 2023-11-08
Miracle-G
Fudan University
Phase 2 Recruiting
NCT06122493 2023-11-08
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Ruijin Hospital
Phase 2 Recruiting
NCT06120127 2023-11-07
IMPROVE
Fudan University
Phase 2 Unknown
NCT05307198 2023-10-10
RAIC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT06022692 2023-09-05
HEAIS001
Zhejiang Hospital
Phase 1/2 Completed
NCT04250948 2023-08-01
Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04652440 2023-04-19
Ablation Combined With PD-1 in HCC: Phase II Study
Sun Yat-sen University
Phase 1/2 Unknown
NCT04030260 2023-03-23
Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04833387 2023-01-11
PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer
Sun Yat-sen University
Phase 2 Active not recruiting